by Virtus | Apr 11, 2026 | Respiratory Preclinical Research
Preclinical efficacy testing respiratory programmes are used to evaluate whether a therapeutic candidate produces a measurable biological effect in respiratory disease models. These studies are a critical step in respiratory drug development, providing data on...
by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Outsourcing vs in-house respiratory research is a common consideration for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo...
by Virtus | Apr 11, 2026 | Viral & Rhinovirus Models
Viral challenge preclinical studies are used in respiratory preclinical research to evaluate how therapeutic candidates perform under controlled viral infection conditions. These studies are commonly applied in respiratory drug development to investigate antiviral...
by Virtus | Apr 11, 2026 | Early-Stage Respiratory Drug Development
Finding the best respiratory CRO in the UK is a key step for biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases. Respiratory drug development requires specialised preclinical models, in vivo respiratory studies,...
by Virtus | Mar 21, 2026 | Respiratory Preclinical Research
Asthma vs COPD preclinical models are frequently compared in respiratory preclinical research because both disease areas require distinct experimental systems to evaluate therapeutic efficacy. While asthma preclinical models focus on immune-mediated airway...
